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Abstract
Estradiol, in addition to its participation in neuroendocrine regulation and sexual behavior, has neuroprotective properties. Different
types of brain injury induce the expression of the enzyme aromatase in reactive astroglia. This enzyme catalyzes the conversion of testos-
terone and other C19 steroids to estradiol. Genetic or pharmacological inhibition of brain aromatase results in marked neurodegeneration
after different forms of mild neurodegenerative stimuli that do not compromise neuronal survival under control conditions. Furthermore,
aromatase mediates neuroprotective effects of precursors of estradiol such as pregnenolone, dehydroepiandrosterone (DHEA) and testos-
terone. These findings strongly suggest that local formation of estradiol in the brain is neuroprotective and that the induction of aromatase
and the consecutive increase in the local production of estradiol are part of the program triggered by the neural tissue to cope with neurode-
generative insults. Aromatase may thus represent an important pharmacological target for therapies conducted to prevent aging-associated
neurodegenerative disorders.
© 2003 Elsevier Ltd. All rights reserved.
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1. Introduction
Decreased levels of estrogen after menopause are asso-
ciated with loss of cognitive skills, the progression of neu-
rodegenerative disorders, increased depressive symptoms,
and other psychological disturbances in women (Fillit,
1994; Paganini-Hill, 1995; Paganini-Hill and Henderson,
1996; Yaffe et al., 1998; Saunders-Pullman et al., 1999;
0301-0082/$ – see front matter © 2003 Elsevier Ltd. All rights reserved.
doi:10.1016/j.pneurobio.2003.09.005
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Sherwin, 1999; Wolf et al., 1999). Therefore, it has been
proposed that estrogen replacement therapies may amelio-
rate the loss of brain function with aging (Costa et al., 1999;
Hogervorst et al., 2000; Resnick and Maki, 2001; Tsang
et al., 2000). This proposition is supported by substan-
tial evidence from animal studies indicating that estradiol
replacement is neuroprotective in both sexes (for recent
reviews, see Chowen et al., 2000; Garcia-Segura et al.,
2001; Green and Simpkins, 2000; Lee and McEwen, 2001;
Wise et al., 2001). Neuroprotective properties have also
been ascribed to estradiol precursors such as pregnenolone
(3-hydroxy-5-pregnen-20-one), dehydroepiandrosterone
(DHEA, 3-hydroxy-5-androstene-17-one) and testos-
terone. However, the results of several studies in humans
have shown that hormonal replacement therapy (HRT) with
estradiol and progesterone has no positive effect for neu-
rodegenerative diseases or stroke and even may have a neg-
ative impact on cognition in postmenopausal women with
Alzheimer’s disease (Shaywitz and Shaywitz, 2000; Fillit,
2002; Azcoitia et al., 2003a; Wise, 2003). Therefore, it is
necessary to establish alternatives to HRT. One possibility
is to increase local estrogen synthesis in the brain and not
in other organs, to avoid health risks associated to periph-
eral actions of estradiol and to avoid the potential negative
effects of progestagens in the brain. However, the potential
neuroprotective role of endogenous estradiol formation has
been largely neglected.
Testosterone and other C19 steroids are converted to
estradiol by aromatase (Fig. 1), an enzyme that consists
of two components: a cytochrome P450 (P450 aro), the
product of the cyp19 gene, and the ubiquitous flavopro-
tein NADPH (reduced nicotinamide adenine dinucleotide
Fig. 1. Estradiol biosynthesis in the central nervous system. Cholesterol is converted to pregnenolone, catalyzed by the cytochrome P450 side-chain
cleavage (P450 scc). Pregnenolone is then converted to progesterone, catalyzed by the 3-hydroxy-steroid dehydrogenase (3-HSD). Pregnenolone
and progesterone can be further converted, via 17-hydroxy-pregnenolone and 17-hydroxy-progesterone, respectively, to dehydroepiandrosterone and
androstenedione. These conversions are catalyzed by the 17-hydroxylase/C17-20-lyase (P450 c17). Then, the 17-hydroxylase/C17-20-lyase (17-HSD)
catalyzes the conversion of DHEA in androstenediol and the conversion of androstenedione in testosterone. Androstenediol is converted to testosterone
by the 3-HSD. Androstenedione and testosterone can be converted to estrone and estradiol, respectively, by aromatase (P450 aro).
phosphate)-cytochrome P450 reductase (Simpson and
Davis, 2001; Kamat et al., 2002). Aromatase is expressed in
the brain (Naftolin et al., 1971), where it is involved in the
regulatory effects of androgens, via conversion to estrogens,
on neural differentiation, neural plasticity, neuroendocrine
function and sexual behavior (MacLusky and Naftolin,
1981; Hutchison, 1991; Lephart, 1996). In this study we
review evidence indicating that local estradiol formation by
aromatase participates in the endogenous mechanisms used
by the brain to cope with neurodegeneration.
2. Aromatase expression is induced after brain
injury
In teleost fishes aromatase is expressed in neurons
(Gelinas and Callard, 1997) as well as in radial glia (Forlano
et al., 2001; Menuet et al., 2003), under normal conditions.
Furthermore, aromatase is expressed in both neuronal and
glial cells in primary cultures of developing zebra finch
telencephalon (Schlinger et al., 1994, 1995). In contrast,
aromatase is expressed exclusively by neurons under nor-
mal conditions in the central nervous system of mammals
(Negri-Cesi et al., 1992; Naftolin, 1994; Lephart, 1996;
Balthazart and Ball, 1998). These neurons are mainly lo-
calized in the lateral septal region, the bed nucleus of the
stria terminalis, the amygdala, several hypothalamic nuclei,
the medial preoptic area, the nucleus accumbens and sev-
eral regions of the cortex, especially in the piriform lobe
(Balthazart et al., 1991; Jakab et al., 1993, 1994; Foidart
et al., 1995). Aromatase immunoreactivity has not been ob-
served in glial cells in the rodent brain in vivo under normal
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circumstances. However, rodent astrocytes isolated from the
cerebral cortex of neonatal rats express aromatase (Zwain
et al., 1997; Zwain and Yen, 1999a). It is possible that spe-
cific culture conditions may induce aromatase expression
in astrocytes. Indeed, recent results (Azcoitia et al., 2003b)
indicate that stressful conditions, such as serum deprivation,
induce aromatase expression in cultured astrocytes. Further-
more, different forms of neurotoxic and mechanical lesions
in the brains of rats and mice increase aromatase activity
and induce de novo expression of the enzyme in reactive
glia (Garcia-Segura et al., 1999a,b). The morphology and
ultrastructure of aromatase-immunoreactive glial cells, to-
gether with the co-expression of the astroglial marker GFAP,
indicate that most, if not all, aromatase-expressing glial
cells are astrocytes (Fig. 2). The induction of aromatase ex-
pression in astrocytes after a brain lesion was accompanied
by a significant increase in aromatase enzymatic activity.
Aromatase-expressing astrocytes are observed in both sexes
Fig. 2. Induction of aromatase in the cerebral cortex of a male mouse after a cryogenic lesion: (a) low magnification showing aromatase immunoreactivity
in the injured cortex; (b) high magnification showing that aromatase immunoreactivity is present in reactive astrocytes. Scale bar: (a) 500m; (b) 50m.
and in all injured brain areas, including the cortex, corpus
callosum, striatum, hippocampus, thalamus and hypotha-
lamus (Garcia-Segura et al., 1999a,b). This indicates that
astrocytes from most brain areas have the potential for ex-
pressing aromatase, and therefore to produce estradiol, in
response to injury. Furthermore, Peterson et al. (2001) have
shown that in the zebra finch brain aromatase mRNA and
protein are rapidly and locally upregulated in glia following
neural injury. This finding suggests that injury-dependent
upregulation of aromatase may be a conserved character-
istic of the vertebrate brain and an important component
of the initial response of neural tissue to injury (Peterson
et al., 2001).
The increased expression of aromatase in injured brain
areas (Garcia-Segura et al., 1999a,b; Peterson et al., 2001)
suggests that this enzyme may be involved in the protection
of nervous tissue by increasing local estrogen levels. Estro-
gen formed by astrocytes may be released as a trophic factor
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for damaged neurons and be involved in the compensatory
restructuring of injured brain tissue. Thus, estrogen released
by astroglia may affect synaptic function, selective regener-
ation of neuronal processes and local cerebral blood flow,
contributing to facilitation of neuronal recovery and reduc-
tion of neuronal death.
3. Aromatase is neuroprotective
3.1. Aromatase-deficient mice are more susceptible to
neurodegeneration in the hippocampus
Systemic administration of domoic acid in mice results
in neurodegenerative damage in the hippocampal formation
(Strain and Tasker, 1991). The neurodegenerative effects of
domoic acid are mediated by an increase in intracellular cal-
cium, as well as by an increased release of glutamate that
results in the activation of NMDA receptors (Berman and
Murray, 1997; Nijjar and Nijjar, 2000). The administration
of domoic acid has been used to assess the effect of aro-
matase deficiency in neurodegeneration (Fig. 3). Aromatase
knock-out (ArKO) male mice and their wild type male lit-
termates were injected with a low dose of domoic acid that
does not induce neurodegeneration in the hippocampus of
normal mice. The number of neurons was then assessed in
the hilus of the dentate gyrus using unbiased morphometric
techniques (Azcoitia et al., 2001). The number of hilar neu-
rons was not significantly different between ArKO mice and
their wild type littermates, indicating that aromatase defi-
ciency does not affect the development and survival of hilar
neurons, at least in young adult animals. However, the num-
ber of hilar neurons in ArKO mice injected with domoic
acid was significantly decreased compared to control ArKO
mice, to wild type controls and to wild type mice injected
with domoic acid (Azcoitia et al., 2001). This finding indi-
Fig. 3. Nissl-stained neurons in the hilus of the dentate gyrus of aromatase knock-out (ArKO) and wild type male mice injected with vehicle or with a
low dose of the neurotoxic domoic acid (i.p., 0.5 mg/kg bw). The low dose of domoic acid did not affect hilar neurons in wild type mice but caused a
significant neuronal loss in the aromatase-deficient mice. Scale bar: 50m.
cates that aromatase deficiency increases the vulnerability
of hilar neurons to neurotoxic degeneration.
3.2. Systemic aromatase inhibition enhances
neurodegeneration in the hippocampus
A further proof of the neuroprotective role of aromatase
has been obtained in intact male rats that were implanted
with an osmotic minipump containing the aromatase in-
hibitor fadrozole (Azcoitia et al., 2001). Kainic acid, a
well-characterized neurotoxin for hilar neurons in the rat
(Buckmaster and Dudek, 1997), was administered at a low
dose that does not affect hilar neurons in intact male rats,
but results in significant neuronal loss in the hilus of cas-
trated rats (Azcoitia et al., 1999a). As expected, the number
of hilar neurons was not affected by kainic acid in control
animals that were not treated with fadrozole. Furthermore,
fadrozole alone did not affect the number of hilar neurons,
indicating that fadrozole is not neurotoxic by itself. How-
ever, animals that were treated with both fadrozole and
kainic acid had a significant decrease in the number of hilar
neurons compared to animals treated with vehicle, to ani-
mals treated with kainic acid alone and to animals treated
with fadrozole alone (Azcoitia et al., 2001). The loss of hi-
lar neurons was accompanied by an increase in the number
of neurons stained with Fluoro-Jade, a marker of dying cells
(Schmued et al., 1997) (Fig. 4). These findings further sup-
port the results obtained with the ArKO mice and confirm
that aromatase is neuroprotective against excitotoxicity.
3.3. Aromatase is neuroprotective in a model of
cerebellar ataxia
The neuroprotective effect of aromatase has been also as-
sessed in a model of cerebellar ataxia produced by the de-
generation of rat inferior olivary nucleus after treatment with
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Fig. 4. Hilus of the dentate gyrus of male Wistar albino rats treated with: (a) vehicle; or (b) the aromatase inhibitor fadrozole (4.16 mg/ml) and injected
with a low dose of the neurotoxic kainic acid (i.p., 7 mg/kg bw). The low dose of kainic acid did not affect hilar neurons in rats treated with vehicle,
but increases labeling with Fluoro-Jade, a marker of dying cells, in rats treated with the aromatase inhibitor. (c) High magnification of the hilus of the
dentate gyrus of a rat treated with fadrozole and kainic acid showing Fluoro-Jade stained neurons. Scale bar: (a and b) 500m; (c) 50m.
3-acetylpirydine (3AP), an antimetabolite of nicotinamide.
Olivary neurons have a very high metabolic rate and are,
therefore, very sensitive to 3AP toxicity. The destruction of
the inferior olive results in loss of climbing fiber input to
cerebellar Purkinje neurons (Baetens et al., 1982), and this
deafferentiation leads to ataxia (Fernandez et al., 1999).
Inferior olivary neurons express aromatase (Sierra et al.,
2003a) and estrogen receptors (Shughrue et al., 1997), and
their activity is affected by estradiol (Smith, 1998). The ac-
tion of estradiol in this nucleus may be important for the
maintenance of motor function that is under the control of
olivo-cerebellar system. Indeed, postmenopausal women re-
ceiving estrogens have a decreased risk of falling and bet-
ter postural balance than non-estrogen users (Naessen et al.,
1997; Randell et al., 2001).
The effect of estradiol administration on the survival of
inferior olivary neurons was assessed in male rats treated
with 3AP (Sierra et al., 2003a). Animals were castrated to
reduce plasma testosterone levels and, therefore, to reduce
the formation of estradiol from its circulating precursor.
Immediately after castration, animals were implanted with
a silicone tube that was either empty or filled with estra-
diol. One week later, animals were injected with 3AP. The
toxicity of 3AP was qualitatively assessed by Nissl-staining
and by a semi-quantitative analysis of neurons stained with
Fluoro-Jade, a marker of dying cells (Schmued et al., 1997).
Furthermore, the number of surviving inferior olivary neu-
rons was assessed by unbiased morphometry using NeuN,
a specific neuronal marker (Mullen et al., 1992). Admin-
istration of 3AP resulted in a significant loss of NeuN
immunoreactive neurons in the inferior olivary nucleus.
The neuronal loss was prevented by estradiol treatment.
Furthermore, estradiol decreased the number of Fluoro-Jade
stained cells in the inferior olive (Sierra et al., 2003a). In
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Fig. 5. Inferior olivary nucleus from male rats treated with: (a) vehicle; or (b) the aromatase inhibitor fadrozole (4.16 mg/ml) and the neurotoxic
3-acetylpirydine (3AP: 30 mg/kg). 3AP did not affect inferior olivary neurons in the rats treated with vehicle, but resulted in a massive neuronal loss in
the rats treated with the aromatase inhibitor.
conclusion, estradiol administration to castrated males re-
sulted in a significant protection of inferior olivary neurons
against 3AP.
Having determined that exogenous estradiol was neuro-
protective for inferior olivary neurons, the next question was
to determine whether endogenous estradiol formation was
neuroprotective as well. The inhibition of aromatase with
fadrozole enhanced the injury produced by 3AP in the in-
ferior olive of intact male rats (Fig. 5). Fadrozole treat-
ment decreased the number of NeuN-expressing neurons that
survived to 3AP and increased the number of Fluoro-Jade
stained dying cells (Sierra et al., 2003a). Therefore, aro-
matase is neuroprotective for inferior olivary neurons.
3.4. Brain aromatase is neuroprotective
The studies mentioned above, on ArKO mice and on
rats after systemic administration of the aromatase in-
hibitor fadrozole, indicate that aromatase is neuroprotective.
However, these studies did not differentiate between brain
aromatase and the peripheral enzyme. To test the role of
local brain aromatase activity in neuroprotection, the aro-
matase inhibitor fadrozole was infused into the right lateral
cerebral ventricle of a group of male rats (Azcoitia et al.,
2001). Fadrozole was administered at a concentration within
the range previously shown to inhibit aromatase in the rat
brain (Bonsall et al., 1992; Clancy et al., 1995; Vagell and
McGinnis, 1997). The number of hilar neurons in the left
hippocampal formation was assessed after an injection of
a low dose of kainic acid that does not induce neurodegen-
eration in intact males. Indeed, the number of hilar neurons
was not affected by this low dose of kainic acid in control
animals. Furthermore, the infusion of fadrozole in the cere-
bral ventricle did not affect the number of hilar neurons in
control animals. This is a further indication that aromatase
activity is not indispensable to maintain hilar neuron sur-
vival under normal circumstances. However, animals that
were treated with both fadrozole and kainic acid showed
a significant decrease in the number of hilar neurons com-
pared to animals treated with vehicle, to animals treated
with kainic acid alone and to animals treated with fadrozole
alone (Azcoitia et al., 2001). This finding indicates that
brain aromatase is neuroprotective.
3.5. Estradiol synthesis mediates neuroprotection by
aromatase
To determine whether the formation of estradiol is in-
volved in the neuroprotective effect of aromatase, male rats
were treated with fadrozole, kainic acid and estradiol. Estra-
diol treatment prevented the neurodegenerative effect of
kainic acid in animals treated with fadrozole. The number
of hilar neurons in animals treated with fadrozole, kainic
acid and estradiol was not significantly different from con-
trol animals and was significantly higher than in animals
treated with fadrozole and kainic acid (Azcoitia et al., 2001).
This finding, showing that the neurodegenerative effect of
aromatase deficiency is counterbalanced by the aromatase
product estradiol, strongly suggests that the neuroprotective
properties of aromatase lies in its ability to catalyze the for-
mation of estradiol rather than reducing testosterone levels.
A similar conclusion has been obtained in the inferior oli-
vary nucleus (Sierra et al., 2003a). The neuronal loss induced
by the aromatase inhibitor fadrozole in the inferior olivary
nucleus of male rats treated with the neurotoxic 3AP is
reverted by estradiol (Sierra et al., 2003a). This indicates that
the toxic effect of fadrozole is due to the inhibition of aro-
matase and not to another unknown effect of the drug. There-
fore, we may conclude that estradiol formation also medi-
ates the neuroprotective effect of aromatase in this model.
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4. Aromatase is involved in neuroprotection by sex
steroid precursors
4.1. Neuroprotection by testosterone is abolished by
aromatase inhibition
Recent studies have shown that the hippocampal hilar
neurons of castrated male mice are more sensitive to do-
moic acid-induced degeneration than the hilar neurons from
intact males (Azcoitia et al., 2001). This was observed us-
ing a low dose of domoic acid that does not affect hilar
neurons in intact animals. However, the same low dose of
domoic acid is able to induce significant neuronal loss in
mice with reduced androgen levels as a result of castration,
indicating that physiological levels of testicular secretions
are neuroprotective. Furthermore, testosterone replacement
prevents domoic acid-induced neuronal loss, indicating that
this estradiol precursor and substrate of aromatase protects
hilar neurons from neurotoxic insults in vivo. Testosterone
promotes neuroprotection in other experimental models as
well. The hormone promotes the survival of specific neu-
ronal populations (Yu, 1982; Jones, 1994; Perez and Kelly,
1996; Rasika et al., 1999), induces motor axon regeneration
in axotomized motoneurons (Yu, 1982; Jones, 1994; Perez
and Kelly, 1996), prevents the hyperphosphorylation of the
microtubule-associated protein tau (Papasozomenos, 1997),
which is abnormally hyperphosphorylated in Alzheimer’s
disease, reduces neuronal secretion of -amyloid pep-
tides associated with Alzheimer’s disease (Gouras et al.,
2000), attenuates -amyloid toxicity (Pike, 2001), protects
granule neurons of the dentate gyrus from adrenalectomy
(Frye and McCormick, 2000) and decreases apolipoprotein
E4-induced cognitive deficits (Raber et al., 2002). Part of the
neuroprotective properties of testosterone may be the result
of the activation of androgen receptors (Ahlbom et al., 2001;
Hammond et al., 2001). However, in the case of protection
of hilar neurons against domoic acid, dihydrotestosterone
(DHT), a 5-reduced metabolite of testosterone that acts on
androgen receptors, is not protective (Azcoitia et al., 2001).
Interestingly, DHT is not ‘aromatizable’ to estradiol. This
suggests that the neuroprotective effect of testosterone in
this experimental model may be due, at least in part, to its
conversion to estradiol by the enzyme aromatase.
To directly assess whether the neuroprotective effect of
testosterone depends on its aromatization to estradiol, cas-
trated male rats were treated with kainic acid in the presence
or absence of the aromatase inhibitor fadrozole (Azcoitia
et al., 2001). Animals were treated with a dose of kainic
acid that causes neurodegeneration in the hilus of the den-
tate gyrus (Azcoitia et al., 1999a). Kainic acid resulted in
significant neuronal loss in the hilus of castrated male rats
compared to animals treated with vehicles. Testosterone
administration prevented the neurodegenerative effect of
kainic acid, confirming the finding obtained in mice. How-
ever, fadrozole prevented neuroprotection by testosterone,
suggesting that testosterone exerts neuroprotective effects
in this experimental model via conversion to estradiol
(Azcoitia et al., 2001). This finding gives additional support
to the idea that aromatase plays a role in neuroprotection
by promoting the formation of estradiol (see Section 3.5).
4.2. Neuroprotection by sex steroid precursors
is abolished by aromatase inhibition
The sex steroid precursors pregnenolone and DHEA have
neuroprotective properties. Pregnenolone reduces neuronal
death in brain cell cultures (Bologa et al., 1987) and pro-
tects mouse hippocampal HT-22 cells against glutamate
and amyloid-beta protein toxicity (Gursoy et al., 2001).
In vivo, pregnenolone protects hippocampal neurons from
kainic acid toxicity (Veiga et al., 2003). Furthermore, preg-
nenolone and its sulfate derivative enhance memory and
cognitive function in different animal models (Flood et al.,
1992; Vallée et al., 1997, 2001; Darnaudery et al., 2002) and
increase neurogenesis in the adult rat hippocampus (Mayo
et al., 2001). DHEA has been shown to protect cells of the
clonal mouse hippocampal cell line HT-22 against the exci-
tatory amino acid glutamate (Cardounel et al., 1999), as well
as primary hippocampal cultured neurons against the neu-
rotoxic actions of AMPA and kainic acid (Kimonides et al.,
1998). In vivo, DHEA protects hippocampal pyramidal
neurons against unilateral infusions of NMDA (Kimonides
et al., 1998) or systemic administration of kainic acid (Veiga
et al., 2003). DHEA and its sulfate derivative have been
shown to protect neurons from other degenerative stimuli
as well, including neurotoxic effects of corticosterone, ox-
idative stress, ischemia and amyloid-beta protein toxicity
(Bologa et al., 1987; Kimonides et al., 1999; Bastianetto
et al., 1999; Cardounel et al., 1999; Lapchak et al., 2000;
Kaasik et al., 2001; Li et al., 2001; Tomas-Camardiel et al.,
2002). Furthermore, DHEA displays memory-enhancing
properties (Flood et al., 1992; Vallée et al., 2001) and in-
creases adult neurogenesis in the hippocampus of rodents
(Karishma and Herbert, 2002).
Pregnenolone and DHEA may exert their neuroprotective
actions by several mechanisms. These may include antiox-
idative effects (Aragno et al., 2000), the rapid modulation
of GABAA, NMDA and sigma 1 receptors (Wu et al., 1991;
Irwin et al., 1992; Majewska, 1992; Bergeron et al., 1996;
Maurice et al., 2001), the down-regulation of glucocorticoid
receptors (Cardounel et al., 1999), the regulation of protein
kinase C signaling (Racchi et al., 2001) or the modulation
of reactive astroglia and reactive microglia (Garcia-Estrada
et al., 1999; Wang et al., 2001). Furthermore, pregnenolone
is able to bind to microtubule-associated protein 2 and to
stimulate microtubule assembly (Murakami et al., 2000;
Plassart-Schiess and Baulieu, 2001), and therefore may ex-
ert effects on the neuronal cytoskeleton.
In addition, neuroprotective effects of pregnenolone and
DHEA may be in part mediated by their conversion to testos-
terone and its consecutive aromatization to estradiol. To de-
termine whether the conversion of pregnenolone and DHEA
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into estradiol is involved in the mechanism of neuroprotec-
tion of these steroids, castrated male rats were implanted
with osmotic minipumps filled with the aromatase inhibitor
fadrozole (Veiga et al., 2003). The administration of fadro-
zole prevented the neuroprotective effects of pregnenolone
and DHEA against kainic acid. The effect of fadrozole was
observed using high doses (100 mg/kg) of the steroids (Veiga
et al., 2003). This finding suggests that estradiol formation
by aromatase may mediate neuroprotective effects of preg-
nenolone and DHEA against excitotoxic-induced neuronal
death in the hippocampus of adult male rats. Therefore, the
aromatization of steroid precursors to estradiol may be part
of an endogenous mechanism activated in the brain tissue
to cope with neurodegeneration. This conclusion does not
exclude alternative or complementary mechanisms for the
neuroprotective effects of pregnenolone and DHEA, includ-
ing the formation of 7-hydroxylated metabolites of DHEA
(Jellinck et al., 2001).
5. Is the brain or the periphery the source of
substrates for brain aromatase?
A question that is still unsolved is whether the nervous
tissue may be a source of substrates for brain aromatase.
Pregnenolone is synthetized in the central nervous system
from cholesterol (Baulieu et al., 2001; Kimoto et al., 2001).
Furthermore, glial cells, at least in vitro, may convert preg-
nenolone to DHEA and may then metabolize DHEA to
testosterone (Zwain and Yen, 1999a,b). There is also ev-
idence that the brain is able to form testosterone in vivo
(Stoffel-Wagner et al., 1999; Stoffel-Wagner, 2001) and
that neural injury enhances local brain steroidogenesis (di
Michele et al., 2000; Lang, 2002; Sierra et al., 2003b). How-
ever, it is still unknown whether local formation of testos-
terone in the brain is of a significant amount to be relevant
for neuroprotection. Furthermore, evidence for conversion
in the brain of androgen precursors, such as pregnenolone
or DHEA, to testosterone is still incomplete. Data obtained
in vitro (Zwain and Yen, 1999a,b; Jellinck et al., 2001)
cannot be directly extrapolated to the real situation in vivo,
since culture conditions can produce spurious upregulation
of steroidogenic enzymes. A complete mapping of steroido-
genic enzymes in the central nervous system, under normal
and pathological conditions, is still lacking.
Further studies should examine the neuroprotective role
of aromatase substrates formed directly in the brain. So far,
studies that have shown that aromatase is neuroprotective
have been performed on males with intact gonads or in
castrated males that have received testosterone replacement
therapy or have been treated with testosterone precursors,
such as pregnenolone and DHEA. Therefore, these animals
have plasmatic sources of substrates for aromatase and not
much can be inferred from these studies on the role of sub-
strates formed locally in the brain. Furthermore, it is clear
that testicular secretions are important for neuroprotec-
tion, since castration increases vulnerability to neurotoxins
(Azcoitia et al., 1999a, 2001). Ovarian hormones are also
important for neuroprotection in females, since vulnera-
bility to neurotoxins is increased by ovariectomy and is
affected by the fluctuation of ovarian hormones during the
estrous cycle (Azcoitia et al., 1999a). Whether, in addition
to peripheral estrogens, local estradiol formation in the
brain plays a neuroprotective role in females is unknown.
It should be noted, however, that aromatase expression is
induced in the injured brain in both sexes (Garcia-Segura
et al., 1999b), suggesting that brain aromatase may also
play some neuroprotective or reparative role in females.
6. Therapeutic perspectives: neuroprotection
and brain aging
The studies reviewed in this paper suggest that the endoge-
nous response of neural tissue to cope with neurodegenera-
tive insults may include the induction of aromatase and the
consecutive increase in the local production of estradiol. Lo-
cally formed estradiol may act on estrogen receptors, which
are known to mediate neuroprotection by estradiol in several
experimental models in vivo (Azcoitia et al., 1999b; Sawada
et al., 2000; Veliskova et al., 2000; Wilson et al., 2000; Wise
et al., 2001). In addition, aromatase may also promote neuro-
protection by increasing local estradiol concentration to lev-
els compatible with the antioxidant neuroprotective effects
of the molecule (Behl and Holsboer, 1999). Since aromatase
is expressed in the adult human brain, including the hip-
pocampus (Sasano et al., 1998; Stoffel-Wagner et al., 1999;
Stoffel-Wagner, 2001), this enzyme may represent a new
molecular target for the therapy or prevention of neurode-
generative diseases, such as Parkinson’s and Alzheimer’s
diseases and other aging-associated brain neurodegenerative
disorders. In this regard, it is important to note that estro-
gen is decreased in the cerebrospinal fluid of women with
aging (Murakami et al., 1999), probably reflecting a de-
crease in local cerebral levels of the hormone. Furthermore,
estrogen is decreased both in plasma and the cerebrospinal
fluid of women with Alzheimer’s disease (Manly et al.,
2000; Schonknecht et al., 2001), suggesting that aromatase
activity or expression may be decreased in these patients.
The role of brain aromatase in neuroprotection calls for
the development of new therapeutic strategies aimed at the
upregulation of the enzyme in the brain without affecting its
expression in other tissues. Considering the possible health
risks of HRT, the regulation of local brain estradiol synthe-
sis may offer an interesting therapeutic alternative for neu-
roprotection. Since the expression of the human aromatase
gene, cyp19, in the various tissues is regulated by the use
of tissue-specific promoters, that are regulated by different
transcription factors and signaling pathways (Simpson and
Davis, 2001; Kamat et al., 2002), it is possible to envisage the
development of selective aromatase modulators, specific for
brain tissue. Further studies are necessary to determine how
L.M. Garcia-Segura et al. / Progress in Neurobiology 71 (2003) 31–41 39
aromatase expression is regulated in the brain and whether
brain aromatase activity or expression is affected with ag-
ing, or under neurodegenerative conditions, in humans.
Note added in proof
A recent study has shown that aromatase contributes to
ischemic neuroprotection in female mice (McCullough et al.,
2003).
Acknowledgements
This study has been supported by grants from the
Commission of the European Communities, specific RTD
programme “Quality of Life and Management of Living
Resources”, QLK6-CT-2000-00179 and from Ministerio de
Ciencia y Tecnologı´a, Spain, SAF 2002-00652.
References
Ahlbom, E., Prins, G.S., Ceccatelli, S., 2001. Testosterone protects
cerebellar granule cells from oxidative stress-induced cell death through
a receptor mediated mechanism. Brain Res. 892, 255–262.
Aragno, M., Mastrocola, R., Brignardello, E., Catalano, M., Robino,
G., Manti, R., Parola, M., Danni, O., Boccuzzi, G., 2000. Dehydro-
epiandrosterone modulates nuclear factor-kappaB activation in
hippocampus of diabetic rats. Diabetes 49, 1924–1931.
Azcoitia, I., Fernandez-Galaz, M.C., Sierra, A., Garcia-Segura, L.M.,
1999a. Gonadal hormones affect neural vulnerability to excitoxin-
induced degeneration. J. Neurocytol. 28, 699–710.
Azcoitia, I., Sierra, A., Garcia-Segura, L.M., 1999b. Neuroprotective
effects of estradiol in the adult rat hippocampus: interaction with
insulin-like growth factor-I signalling. J. Neurosci. Res. 58, 815–822.
Azcoitia, I., Sierra, A., Veiga, S., Honda, S., Harada, N., Garcia-Segura,
L.M., 2001. Brain aromatase is neuroprotective. J. Neurobiol. 47, 318–
329.
Azcoitia, I., DonCarlos, L.L., Garcia-Segura, L.M., 2003a. Are gonadal
steroid hormones involved in disorders of brain aging? Aging Cell 2,
31–37.
Azcoitia, I., Sierra, A., Veiga, S., Garcia-Segura, L.M., 2003b. Aromatase
expression by reactive astroglia is neuroprotective. Ann. N. Y. Acad.
Sci., in press.
Baetens, D., Garcia-Segura, L.M., Perrelet, A., 1982. Effects of climbing
fiber destruction on large dendrite spines of Purkinje cells. Exp. Brain
Res. 48, 256–262.
Balthazart, J., Ball, G.F., 1998. New insights into the regulation and
function of brain estrogen synthase (aromatase). Trends Neurosci. 21,
243–249.
Balthazart, J., Foidart, A., Surlemont, C., Harada, N., 1991. Distribution
of aromatase-immunoreactive cells in the mouse forebrain. Cell Tiss.
Res. 263, 71–79.
Bastianetto, S., Ramassamy, C., Poirier, J., Quirion, R., 1999.
Dehydroepiandrosterone (DHEA) protects hippocampal cells from
oxidative stress-induced damage. Mol. Brain Res. 66, 35–41.
Baulieu, E.E., Robel, P., Schumacher, M., 2001. Neurosteroids: beginning
of the story. Int. Rev. Neurobiol. 46, 1–32.
Behl, C., Holsboer, F., 1999. The female sex hormone oestrogen as a
neuroprotectant. Trends Pharmacol. Sci. 20, 441–444.
Bergeron, R., de Montigny, C., Debonnel, G., 1996. Potentiation of
neuronal NMDA response induced by dehydroepiandrosterone and
its suppression by progesterone: effects mediated via  receptors. J.
Neurosci. 16, 1193–1202.
Berman, F.W., Murray, T.F., 1997. Domoic acid neurotoxicity in cultured
cerebellar granule neurons is mediated predominantly by NMDA
receptors that are activated as a consequence of excitatory amino acid
release. J. Neurochem. 69, 693–703.
Bologa, L., Sharma, J., Roberts, E., 1987. Dehydroepiandrosterone and
its sulfated derivative reduce neuronal death and enhance astrocytic
differentiation in brain cell cultures. J. Neurosci. Res. 17, 225–234.
Bonsall, R.W., Clancy, A.N., Michael, R.P., 1992. Effects of the
non-steroidal aromatase inhibitor, Fadrozole, on sexual behavior in
male rats. Horm. Behav. 26, 240–254.
Buckmaster, P.S., Dudek, F.E., 1997. Neuron loss, granule cell axon
reorganization, and functional changes in the dentate gyrus of epileptic
kainate-treated rats. J. Comp. Neurol. 385, 385–404.
Cardounel, A., Regelson, W., Kalimi, M., 1999. Dehydroepiandrosterone
protects hippocampal neurons against neurotoxin-induced cell death:
mechanism of action. Proc. Soc. Exp. Biol. Med. 222, 145–149.
Chowen, J.A., Azcoitia, I., Cardona-Gomez, G.P., Garcia-Segura, L.M.,
2000. Sex steroids and the brain: lessons from animal studies. J. Pediatr.
Endocrinol. Metab. 13, 1045–1066.
Clancy, A.N., Zumpe, D., Michael, R.P., 1995. Intracerebral infusion of an
aromatase inhibitor, sexual behavior and brain estrogen receptor-like
immunoreactivity in intact male rats. Neuroendocrinology 61, 98–111.
Costa, M.M., Reus, V.I., Wolkowitz, O.M., Manfredi, F., Lieberman,
M., 1999. Estrogen replacement therapy and cognitive decline in
memory-impaired post-menopausal women. Biol. Psychiatry 46, 182–
188.
Darnaudery, M., Pallares, M., Piazza, P., Le Moal, M., Mayo, W., 2002.
The neurosteroid pregnenolone sulfate infused into the medial septum
nucleus increases hippocampal acetylcholine and spatial memory in
rats. Brain Res. 951, 237–242.
di Michele, F., Lekieffre, D., Pasini, A., Bernardi, G., Benavides, J.,
Romeo, E., 2000. Increased neurosteroids synthesis after brain and
spinal cord injury in rats. Neurosci. Lett. 284, 65–68.
Fernandez, A.M., Planas, B., Torres-Aleman, I., 1999. Neuroprotective
actions of peripherally administered insulin-like growth factor I in the
injured olivo-cerebellar pathway. Eur. J. Neurosci. 11, 2019–2030.
Fillit, H., 1994. Estrogens in the pathogenesis and treatment of
Alzheimer’s disease in postmenopausal women. Ann. N. Y. Acad. Sci.
743, 233–238.
Fillit, H.M., 2002. The role of hormone replacement therapy in the
prevention of Alzheimer disease. Arch. Intern. Med. 162, 1934–1942.
Flood, J.F., Morley, J.E., Roberts, E., 1992. Memory-enhancing effects in
male mice of pregnenolone and steroids metabolically derived from it.
Proc. Natl. Acad. Sci. U.S.A. 89, 1567–1571.
Foidart, A., Harada, N., Balthazart, J., 1995. Aromatase-immunoreactive
cells are present in mouse brain areas that are known to express high
levels of aromatase activity. Cell Tissue Res. 280, 561–574.
Forlano, P.M., Deitcher, D.L., Myers, D.A., Bass, A.H., 2001. Anatomical
distribution and cellular basis for high levels of aromatase activity in
the brain of teleost fish: aromatase enzyme and mRNA expression
identify glia as source. J. Neurosci. 21, 8943–8955.
Frye, C.A., McCormick, C.M., 2000. Androgens are neuroprotective in
the dentate gyrus of adrenalectomized female rats. Stress 3, 185–194.
Garcia-Estrada, J., Luquin, S., Fernandez, A.M., Garcia-Segura,
L.M., 1999. Dehydroepiandrosterone, pregnenolone and sex steroids
down-regulate reactive astroglia in the male rat brain after a penetrating
brain injury. Int. J. Dev. Neurosci. 17, 145–151.
Garcia-Segura, L.M., Naftolin, F., Hutchison, J.B., Azcoitia, I., Chowen,
J.A., 1999a. Role of astroglia in estrogen regulation of synaptic
plasticity and brain repair. J. Neurobiol. 40, 574–584.
Garcia-Segura, L.M., Wozniak, A., Azcoitia, I., Rodriguez, J.R.,
Hutchison, R.E., Hutchison, J.B., 1999b. Aromatase expression by
astrocytes after brain injury: implications for local estrogen formation
in brain repair. Neuroscience 89, 567–578.
Garcia-Segura, L.M., Azcoitia, I., DonCarlos, L.L., 2001. Neuroprotection
by estradiol. Prog. Neurobiol. 63, 29–60.
40 L.M. Garcia-Segura et al. / Progress in Neurobiology 71 (2003) 31–41
Gelinas, D., Callard, G.V., 1997. Immunolocalization of aromatase-
and androgen receptor-positive neurons in the goldfish brain. Gen.
Comp. Endocrinol. 106, 155–168.
Gouras, G.K., Xu, H., Gross, R.S., Greenfield, J.P., Hai, B., Wang,
R., Greengard, P., 2000. Testosterone reduces neuronal secretion of
Alzheimer’s beta-amyloid peptides. Proc. Natl. Acad. Sci. U.S.A. 97,
1202–1205.
Green, P.S., Simpkins, J.W., 2000. Neuroprotective effects of estrogens:
potential mechanisms of action. Int. J. Dev. Neurosci. 18, 347–358.
Gursoy, E., Cardounel, A., Kalimi, M., 2001. Pregnenolone protects mouse
hippocampal (HT-22) cells against glutamate and amyloid beta protein
toxicity. Neurochem. Res. 26, 15–21.
Hammond, J., Le, Q., Goodyer, C., Gelfand, M., Trifiro, M., LeBlanc,
A., 2001. Testosterone-mediated neuroprotection through the androgen
receptor in human primary neurons. J. Neurochem. 77, 1319–1326.
Hogervorst, E., Williams, J., Budge, M., Riedel, W., Jolles, J., 2000. The
nature of the effect of female gonadal hormone replacement therapy
on cognitive function in post-menopausal women: a meta-analysis.
Neuroscience 101, 485–512.
Hutchison, J.B., 1991. Hormonal control of behaviour: steroid action in
the brain. Curr. Opin. Neurobiol. 1, 562–570.
Irwin, R.P., Maragakis, N.J., Rogawski, M.A., Purdy, R.H., Farb, D.H.,
Paul, S.M., 1992. Pregnenolone sulphate augments NMDA receptor
mediated increases in intracellular Ca2+ in cultured rat hippocampal
neurons. Neurosci. Lett. 141, 30–34.
Jakab, R.L., Horvath, T.L., Leranth, C., Harada, N., Naftolin, F., 1993.
Aromatase immunoreactivity in the rat brain: gonadectomy-sensitive
hypothalamic neurons and an unresponsive “limbic ring” of the lateral
septum-bed nucleus-amygdala complex. J. Steroid Biochem. Mol. Biol.
44, 481–498.
Jakab, R.L., Harada, N., Naftolin, F., 1994. Aromatase (estrogen
synthetase)-immunoreactive neurons in the rat septal area. A light and
electron microscopic study. Brain Res. 664, 85–93.
Jellinck, P.H., Lee, S.J., McEwen, B.S., 2001. Metabolism of
dehydroepiandrosterone by rat hippocampal cells in culture: possible
role of aromatization and 7-hydroxylation in neuroprotection. J. Steroid
Biochem. Mol. Biol. 78, 313–317.
Jones, K.J., 1994. Androgenic enhancement of motor neuron regeneration.
Ann. N. Y. Acad. Sci. 743, 141–161.
Kaasik, A., Kalda, A., Jaako, K., Zharkovsky, A., 2001. Dehydroepian-
drosterone sulphate prevents oxygen–glucose deprivation-induced
injury in cerebellar granule cell culture. Neuroscience 102, 427–432.
Kamat, A., Hinshelwood, M.M., Murry, B.A., Mendelson, C.R., 2002.
Mechanisms in tissue-specific regulation of estrogen biosynthesis in
humans. Trends Endocrinol. Metab. 13, 122–128.
Karishma, K.K., Herbert, J., 2002. Dehydroepiandrosterone (DHEA)
stimulates neurogenesis in the hippocampus of the rat, promotes
survival of newly formed neurons and prevents corticosterone-induced
suppression. Eur. J. Neurosci. 16, 445–453.
Kimonides, V.G., Khatibi, N.H., Svendsen, C.N., Sofroniew, M.V.,
Herbert, J., 1998. Dehydroepiandrosterone (DHEA) and DHEA-sulfate
(DHEAS) protect hippocampal neurons against excitatory amino
acid-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 95, 1852–
1857.
Kimonides, V.G., Spillantini, M.G., Sofroniew, M.V., Fawcett, J.W.,
Herbert, J., 1999. Dehydroepiandrosterone antagonizes the neurotoxic
effects of corticosterone and translocation of stress-activated protein
kinase 3 in hippocampal primary cultures. Neuroscience 89, 429–436.
Kimoto, T., Tsurugizawa, T., Ohta, Y., Makino, J., Tamura, H.,
Hojo, Y., Takata, N., Kawato, S., 2001. Neurosteroid synthesis
by cytochrome P450-containing systems localized in the rat brain
hippocampal neurons: N-methyl-d-aspartate and calcium-dependent
synthesis. Endocrinology 142, 3578–3589.
Lang, S., 2002. The role of peripheral benzodiazepine receptors (PBRs)
in CNS pathophysiology. Curr. Med. Chem. 9, 1411–1415.
Lapchak, P.A., Chapman, D.F., Nunez, S.Y., Zivin, J.A., 2000.
Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal
cord ischemia model: possible involvement of GABA(A) receptors.
Stroke 31, 1953–1956.
Lee, S.J., McEwen, B.S., 2001. Neurotrophic and neuroprotective actions
of estrogens and their therapeutic implications. Annu. Rev. Pharmacol.
Toxicol. 41, 569–591.
Lephart, E.D., 1996. A review of brain aromatase cytochrome P450. Brain
Res. Rev. 22, 1–26.
Li, H., Klein, G., Sun, P., Buchan, A.M., 2001. Dehydroepiandrosterone
(DHEA) reduces neuronal injury in a rat model of global cerebral
ischemia. Brain Res. 888, 263–266.
MacLusky, N.J., Naftolin, F., 1981. Sexual differentiation of the central
nervous system. Science 211, 1294–1302.
Majewska, M.D., 1992. Neurosteroids: endogenous bimodal modulators
of the GABAA receptor. Mechanism of action and physiological
significance. Prog. Neurobiol. 38, 379–395.
Manly, J.J., Merchant, C.A., Jacobs, D.M., Small, S.A., Bell, K., Ferin,
M., Mayeux, R., 2000. Endogenous estrogen levels and Alzheimer’s
disease among postmenopausal women. Neurology 54, 833–837.
Maurice, T., Urani, A., Phan, V.L., Romieu, P., 2001. The interaction
between neuroactive steroids and the sigma1 receptor function:
behavioral consequences and therapeutic opportunities. Brain Res. Rev.
37, 116–132.
Mayo, W., Le Moal, M., Abrous, D.N., 2001. Pregnenolone sulfate
and aging of cognitive functions: behavioral, neurochemical, and
morphological investigations. Horm. Behav. 40, 215–217.
McCullough, L.D., Blizzard, K., Simpson, E.R., Oz, O.K., Hurn, P.D.,
2003. Aromatase cytochrome P450 and extragonadal estrogen play a
role in ischemic neuroprotection. J. Neurosci. 23, 8701–8705.
Menuet, A., Anglade, I., Le Guevel, R., Pellegrini, E., Pakdel, F., Kah, O.,
2003. Distribution of aromatase mRNA and protein in the brain and
pituitary of female rainbow trout: comparison with estrogen receptor
alpha. J. Comp. Neurol. 462, 180–193.
Mullen, R.J., Buck, C.R., Smith, A.M., 1992. NeuN, a neuronal specific
nuclear protein in vertebrates. Development 116, 201–211.
Murakami, K., Nakagawa, T., Shozu, M., Uchide, K., Koike, K., Inoue,
M., 1999. Changes with aging of steroidal levels in the cerebrospinal
fluid of women. Maturitas 33, 71–80.
Murakami, K., Fellous, A., Baulieu, E.E., Robel, P., 2000. Pregnenolone
binds to microtubule-associated protein 2 and stimulates microtubule
assembly. Proc. Natl. Acad. Sci. U.S.A. 97, 3579–3584.
Naessen, T., Lindmark, B., Larsen, H.C., 1997. Better postural balance
in elderly women receiving estrogens. Am. J. Obstet. Gynecol. 177,
412–416.
Naftolin, F., 1994. Brain aromatization of androgens. J. Reprod. Med. 39,
257–261.
Naftolin, F., Ryan, K.J., Petro, Z., 1971. Aromatization of androstenedione
by the diencephalon. J. Clin. Endocrinol. Metab. 33, 368–370.
Negri-Cesi, P., Melcangi, R.C., Celotti, F., Martini, L., 1992. Aromatase
activity in cultured brain cells: difference between neurons and glia.
Brain Res. 589, 327–332.
Nijjar, M.S., Nijjar, S.S., 2000. Domoic acid-induced neurodegeneration
resulting in memory loss is mediated by Ca2+ overload and inhibition
of Ca2+ + calmodulin-stimulated adenylate cyclase in rat brain. Int.
J. Mol. Med. 6, 377–389.
Paganini-Hill, A., 1995. Estrogen replacement therapy and stroke. Prog.
Cardiovasc. Dis. 38, 223–242.
Paganini-Hill, A., Henderson, V.W., 1996. Estrogen replacement therapy
and risk of Alzheimer disease. Arch. Intern. Med. 156, 2213–2217.
Papasozomenos, S.C., 1997. The heat shock-induced hyperphosphoryla-
tion of tau is estrogen-independent and prevented by androgens:
implications for Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 94,
6612–6617.
Perez, J., Kelly, D.B., 1996. Trophic effects of androgen receptor
expression and the survival of laryngeal motor neurons after axotomy.
J. Neurosci. 16, 6625–6633.
Peterson, R.S., Saldanha, C.J., Schlinger, B.A., 2001. Rapid upregulation
of aromatase mRNA and protein following neural injury in the zebra
finch (Taeniopygia guttata). J. Neuroendocrinol. 13, 317–323.
L.M. Garcia-Segura et al. / Progress in Neurobiology 71 (2003) 31–41 41
Pike, C.J., 2001. Testosterone attenuates beta-amyloid toxicity in cultured
hippocampal neurons. Brain Res. 919, 160–165.
Plassart-Schiess, E., Baulieu, E.E., 2001. Neurosteroids: recent findings.
Brain Res. Rev. 37, 133–140.
Raber, J., Bongers, G., LeFevour, A., Buttini, M., Mucke, L., 2002.
Androgens protect against apolipoprotein E4-induced cognitive deficits.
J. Neurosci. 22, 5204–5209.
Racchi, M., Govoni, S., Solerte, S.B., Galli, C.L., Corsini, E., 2001.
Dehydroepiandrosterone and the relationship with aging and memory:
a possible link with protein kinase C functional machinery. Brain Res.
Rev. 37, 287–293.
Randell, K.M., Honkanen, R.J., Komulainen, M.H., Tuppurainen, M.T.,
Kroger, H., Saarikoski, S., 2001. Hormone replacement therapy and
risk of falling in early postmenopausal women—a population-based
study. Clin. Endocrinol. (Oxford) 54, 769–774.
Rasika, S., Alvarez-Buylla, A., Nottebohm, F., 1999. BDNF mediates the
effects of testosterone on the survival of new neurons in an adult brain.
Neuron 22, 53–62.
Resnick, S.M., Maki, P.M., 2001. Effects of hormone replacement therapy
on cognitive and brain aging. Ann. N. Y. Acad. Sci. 949, 203–214.
Sasano, H., Takashashi, K., Satoh, F., Nagura, H., Harada, N., 1998.
Aromatase in the human central nervous system. Clin. Endocrinol.
(Oxford) 48, 325–329.
Saunders-Pullman, R., Gordon-Elliott, J., Parides, M., Fahn, S., Saunders,
H.R., Bressman, S., 1999. The effect of estrogen replacement on early
Parkinson’s disease. Neurology 52, 1417–1421.
Sawada, M., Alkayed, N.J., Goto, S., Crain, B.J., Traystman, R.J., Shaivitz,
A., Nelson, R.J., Hurn, P.D., 2000. Estrogen receptor antagonist ICI
182,780 exacerbates ischemic injury in female mouse. J. Cereb. Blood
Flow Metab. 20, 112–118.
Schlinger, B.A., Amur-Umarjee, S., Shen, P., Campagnoni, A.T., Arnold,
A.P., 1994. Neuronal and non-neuronal aromatase in primary cultures
of developing zebra finch telencephalon. J. Neurosci. 14, 7541–7552.
Schlinger, B.A., Amur-Umarjee, S., Campagnoni, A.T., Arnold, A.P.,
1995. 5 beta-reducatse and other androgen-metabolizing enzymes
in primary cultures of developing zebra finch telencephalon. J.
Neuroendocrinol. 7, 187–192.
Schonknecht, P., Pantel, J., Klinga, K., Jensen, M., Hartmann, T., Salbach,
B., Schroder, J., 2001. Reduced cerebrospinal fluid estradiol levels are
associated with increased beta-amyloid levels in female patients with
Alzheimer’s disease. Neurosci. Lett. 307, 122–124.
Schmued, L.C., Albertson, C., Slikker Jr., W., 1997. Fluoro-Jade: a novel
fluorochrome for the sensitive and reliable histochemical localization
of neuronal degeneration. Brain Res. 751, 37–46.
Shaywitz, B.A., Shaywitz, S.E., 2000. Estrogen and Alzheimer disease:
plausible theory, negative clinical trial. J. Am. Med. Assoc. 283, 1055–
1056.
Sherwin, B.B., 1999. Can estrogen keep you smart? Evidence from clinical
studies. J. Psychiatry Neurosci. 24, 315–321.
Shughrue, P.J., Lane, M.V., Merchenthaler, I., 1997. Comparative
distribution of estrogen receptor-alpha and -beta mRNA in the rat
central nervous system. J. Comp. Neurol. 388, 507–525.
Sierra, A., Azcoitia, I., Garcia-Segura, L.M., 2003a. Endogenous estrogen
formation is neuroprotective in a model of cerebellar ataxia. Endocrine
21, 43–52.
Sierra, A., Lavaque, E., Perez-Martin, M., Azcoitia, I., Hales, D.B.,
Garcia-Segura, L.M., 2003b. Steroidogenic acute regulatory protein
in the rat brain: cellular distribution, developmental regulation and
overexpression after injury. Eur. J. Neurosci. 18, 1458–1467.
Simpson, E.R., Davis, S.R., 2001. Minireview: aromatase and
the regulation of estrogen biosynthesis—some new perspectives.
Endocrinology 142, 4589–4594.
Smith, S.S., 1998. Estrous hormones enhance coupled, rhythmic olivary
discharge in correlation with facilitated limb stepping. Neuroscience
82, 83–95.
Stoffel-Wagner, B., 2001. Neurosteroid metabolism in the human brain.
Eur. J. Endocrinol. 145, 669–679.
Stoffel-Wagner, B., Watzka, M., Schramm, J., Bidlingmaier, F.,
Klingmuller, D., 1999. Expression of CYP19 (aromatase) mRNA in
different areas of the human brain. J. Steroid Biochem. Mol. Biol. 70,
237–241.
Strain, S.M., Tasker, R.A., 1991. Hippocampal damage produced by
systemic injections of domoic acid in mice. Neuroscience 44, 343–352.
Tomas-Camardiel, M., Sanchez-Hidalgo, M.C., Sanchez del Pino,
M.J., Navarro, A., Machado, A., Cano, J., 2002. Comparative
study of the neuroprotective effect of dehydroepiandrosterone and
17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat
striatum. Neuroscience 109, 569–584.
Tsang, K.L., Ho, S.L., Lo, S.K., 2000. Estrogen improves motor disability
in parkinsonian postmenopausal women with motor fluctuations.
Neurology 54, 2292–2298.
Vagell, M.E., McGinnis, M.Y., 1997. The role of aromatization in the
restoration of male rat reproductive behavior. J. Neuroendocrinol. 9,
415–421.
Vallée, M., Mayo, W., Darnaudéry, M., Corpéchot, C., Young, J.,
Koehl, M., Le Moal, M., Baulieu, E.E., Robel, P., Simon, H., 1997.
Neurosteroids: deficient cognitive performance in aged rats depends
on low pregnenolone sulfate levels in the hippocampus. Proc. Natl.
Acad. Sci. U.S.A. 94, 14865–14870.
Vallée, M., Mayo, W., Le Moal, M., 2001. Role of pregnenolone,
dehydroepiandrosterone and their sulfate esters on learning and memory
in cognitive aging. Brain Res. Rev. 37, 301–312.
Veiga, S., Garcia-Segura, L.M., Azcoitia, I., 2003. Neuroprotection by the
steroids pregnenolone and dehydroepiandrosterone is mediated by the
enzyme aromatase. J. Neurobiol. 56, 398–406.
Veliskova, J., Velisek, L., Galanopoulou, A.S., Sperber, E.F., 2000.
Neuroprotective effects of estrogens on hippocampal cells in adult
female rats after status epilepticus. Epilepsia 41 (Suppl. 6), S30–35.
Wang, M.J., Huang, H.M., Chen, H.L., Kuo, J.S., Jeng, K.C., 2001.
Dehydroepiandrosterone inhibits lipopolysaccharide-induced nitric
oxide production in BV-2 microglia. J. Neurochem. 77, 830–838.
Wilson, M.E., Dubal, D.B., Wise, P.M., 2000. Estradiol protects against
injury-induced cell death in cortical explant cultures: a role for estrogen
receptors. Brain Res. 873, 235–242.
Wise, P.M., 2003. Estrogens: protective or risk factors in brain function?
Prog. Neurobiol. 69, 181–191.
Wise, P.M., Dubal, D.B., Wilson, M.E., Rau, S.W., Liu, Y., 2001.
Estrogens: trophic and protective factors in the adult brain. Front.
Neuroendocrinol. 22, 33–66.
Wolf, O.T., Kudielka, B.M., Hellhammer, D.H., Torber, S., McEwen, B.S.,
Kirschbaum, C., 1999. Two weeks of transdermal estradiol treatment
in postmenopausal elderly women and its effect on memory and mood:
verbal memory changes are associated with the treatment induced
estradiol levels. Psychoneuroendocrinology 24, 727–741.
Wu, F.S., Gibbs, T.T., Farb, D.H., 1991. Pregnenolone sulphate: a
positive allosteric modulator at the N-methyl-d-aspartate receptor. Mol.
Pharmacol. 40, 333–336.
Yaffe, K., Sawaya, G., Lieberburg, I., Grady, D., 1998. Estrogen therapy
in postmenopausal women: effects on cognitive function and dementia.
J. Am. Med. Assoc. 279, 688–695.
Yu, W.H., 1982. Effect of testosterone on the regeneration of the
hypoglossal nerve in rats. Exp. Neurol. 77, 129–141.
Zwain, I.H., Yen, S.S.C., 1999a. Dehydroepiandrosterone: biosynthesis
and metabolism in the brain. Endocrinology 140, 880–887.
Zwain, I.H., Yen, S.S.C., 1999b. Neurosteroidogenesis in astrocytes,
oligodendrocytes, and neurons of cerebral cortex of rat brain.
Endocrinology 140, 3843–3852.
Zwain, I.H., Yen, S.S.C., Cheng, C.Y., 1997. Astrocytes cultured in vitro
produce estradiol-17 and express aromatase cytochrome P-450 (P-450
AROM) mRNA. Biochim. Biophys. Acta 1334, 338–348.
